Literature DB >> 24642256

Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.

Adwait Anand Godbole1, Wareed Ahmed1, Rajeshwari Subray Bhat1, Erin K Bradley2, Sean Ekins3, Valakunja Nagaraja4.   

Abstract

m-AMSA, an established inhibitor of eukaryotic type II topoisomerases, exerts its cidal effect by binding to the enzyme-DNA complex thus inhibiting the DNA religation step. The molecule and its analogues have been successfully used as chemotherapeutic agents against different forms of cancer. After virtual screening using a homology model of the Mycobacterium tuberculosis topoisomerase I, we identified m-AMSA as a high scoring hit. We demonstrate that m-AMSA can inhibit the DNA relaxation activity of topoisomerase I from M. tuberculosis and Mycobacterium smegmatis. In a whole cell assay, m-AMSA inhibited the growth of both the mycobacteria.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mycobacterium tuberculosis; Topoisomerase inhibitors; Type I topoisomerase; m-AMSA

Mesh:

Substances:

Year:  2014        PMID: 24642256     DOI: 10.1016/j.bbrc.2014.03.029

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Probe discovery: Disentangling gene networks.

Authors:  Finbarr Hayes
Journal:  Nat Chem Biol       Date:  2016-01       Impact factor: 15.040

Review 2.  Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.

Authors:  Yuk-Ching Tse-Dinh
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 3.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

Review 4.  Learning from the past for TB drug discovery in the future.

Authors:  Katarína Mikušová; Sean Ekins
Journal:  Drug Discov Today       Date:  2016-10-04       Impact factor: 7.851

5.  RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.

Authors:  Abeer Al-Zubaidi; Chen-Yi Cheung; Gregory M Cook; George Taiaroa; Valerie Mizrahi; J Shaun Lott; Stephanie S Dawes
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

6.  Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold.

Authors:  Kemin Tan; Nan Cao; Bokun Cheng; Andrzej Joachimiak; Yuk-Ching Tse-Dinh
Journal:  J Mol Biol       Date:  2015-12-03       Impact factor: 5.469

7.  Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.

Authors:  Shayna Sandhaus; Thirunavukkarasu Annamalai; Greg Welmaker; Richard A Houghten; Carlos Paz; Pamela K Garcia; Angelo Andres; Gagandeep Narula; Carolina Rodrigues Felix; Sandra Geden; Mandy Netherton; Rashmi Gupta; Kyle H Rohde; Marc A Giulianotti; Yuk-Ching Tse-Dinh
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Illustrating and homology modeling the proteins of the Zika virus.

Authors:  Sean Ekins; John Liebler; Bruno J Neves; Warren G Lewis; Megan Coffee; Rachelle Bienstock; Christopher Southan; Carolina H Andrade
Journal:  F1000Res       Date:  2016-03-03

9.  Amsacrine Derivatives Selectively Inhibit Mycobacterial Topoisomerase I (TopA), Impair M. smegmatis Growth and Disturb Chromosome Replication.

Authors:  Marcin J Szafran; Marta Kołodziej; Patrycja Skut; Brahmam Medapi; Agnieszka Domagała; Damian Trojanowski; Jolanta Zakrzewska-Czerwińska; Dharmarajan Sriram; Dagmara Jakimowicz
Journal:  Front Microbiol       Date:  2018-07-17       Impact factor: 5.640

Review 10.  Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.

Authors:  Michael A Reiche; Digby F Warner; Valerie Mizrahi
Journal:  Front Mol Biosci       Date:  2017-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.